Money and deals are flowing into the companies founded on CRISPR technology, which promises to enable the precise editing of genomes.
CRISPR/Cas9 stands for “clustered, regularly interspaced, short palindromic repeat” and an associated protein (not always mentioned). A brief video introduction from UC Berkeley’s Innovative Genomics Initiative (IGI) gives an overview of the editing process. A webinar put on by Genetic Engineering & Biotechnology News, featuring Harvard professors George Church and Feng Zhang, gives more detail.
The first prominent company intending to exploit this technology was Editas, which was founded by five of the most prominent scientists in the field. Editas recently announced licensing deals with Massachusetts General Hospital, Duke University, Harvard University, and the Broad Institute, all for intellectual property related to the use of CRISPR/Cas9 as well as TALEN genome-editing technologies [press release pdfs, 1, 2, 3].
BioIt World has more about the implications of these deals for prospects of both ex vivo and in vivo drug development, and quotes CEO Katrine Bosley as saying they are “at least a couple years from the clinic.” In a press release, Bosley said:
“We all share the goal of translating this cutting-edge science into breakthrough medicines for people with genetically-driven diseases.”
Generally, Editas is looking to create “robust medicines” that will enable “the prevention and treatment of human or animal disease, and broad agricultural use.”
This superficially bland ambition has some worrying overtones. One major concern is the apparent assumption that genomics can reliably predict disease in time to prevent it, which is only true of a small number of genetic disorders.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.